14575-59-8

Usage

Uses

Used in Pharmaceutical Industry:
1-phenyl-1H-1,2,4-triazole-3,5-diamine is used as an active pharmaceutical ingredient for the development of drugs targeting various health conditions. Its unique chemical structure allows it to interact with biological targets, making it a promising candidate for medicinal chemistry.
Used in Agrochemical Industry:
In the agrochemical sector, 1-phenyl-1H-1,2,4-triazole-3,5-diamine is used as a triazole fungicide, herbicide, and antifungal agent. Its ability to control and prevent the growth of unwanted organisms in agricultural settings contributes to increased crop yields and protection against diseases.
Used in Organic Synthesis:
1-phenyl-1H-1,2,4-triazole-3,5-diamine serves as a building block and reagent in organic synthesis. Its functional groups and structural features make it a valuable component in the creation of various organic compounds, including dyes, pigments, and other specialty chemicals.
Used in Dye and Pigment Production:
As an intermediate in the production of dyes and pigments, 1-phenyl-1H-1,2,4-triazole-3,5-diamine contributes to the development of colorants for a wide range of applications, such as textiles, plastics, and printing inks. Its chemical properties enable the creation of stable and vibrant colorants.
Used in Anticancer and Anti-tumor Research:
1-phenyl-1H-1,2,4-triazole-3,5-diamine has demonstrated potential anti-cancer and anti-tumor properties, making it a subject of interest for researchers in the field of oncology. Its ability to target and inhibit the growth of cancer cells could lead to the development of novel therapeutic agents for cancer treatment.
Overall, 1-phenyl-1H-1,2,4-triazole-3,5-diamine is a multifaceted compound with applications spanning pharmaceuticals, agrochemicals, organic synthesis, dye and pigment production, and cancer research. Its versatility and potential for further development make it an important chemical entity in various scientific and industrial domains.

InChI:InChI=1/C8H9N5/c9-7-11-8(10)13(12-7)6-4-2-1-3-5-6/h1-5H,(H4,9,10,11,12)

Upstream product

• 420-04-2 CYANAMID 
• 4254-63-1 anilino-guanidine; hydrochloride 
• 124-46-9 guanidine hydrogen carbonate 
• 56-03-1 BIGUANIDE 
• 100-63-0 phenylhydrazine 
• 59-88-1 phenylhydrazine hydrochloride 
• 127099-85-8 N-Cyanoguanidine 
• 1228305-28-9 ethyl 3-(5-amino-1-phenyl-1H-1,2,4-triazol-3-ylamino)but-2-enoate 

Downstream Products

• 112599-50-5 N³,N⁵-bis-(2-acetyl-3-oxo-but-1-enyl)-1-phenyl-1H-[1,2,4]triazole-3,5-diyldiamine 

Relevant academic research and scientific papers

Concise and regiospecific syntheses of tri-substituted 1,2,4-triazoles

Novel tri-substituted 1,2,4-triazoles are synthesized via complementary, regiospecific routes as part of a lead finding exercise. A key feature of one of the syntheses is recognition of an intrinsic regioselectivity toward deprotonation in the 1-phenylguanazole substrate.

ASYMMETRIC TRIAZOLE BENZAMIDE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME

The present disclosure is directed to asymmetric triazole benzamide compounds of formula (I) and formula (II), pharmaceutical compositions thereof and methods for modulating or activating a Parkin ligase The present disclosure is also directed to methods of treating and/or reducing the incidence of diseases or conditions related to the activation of Parkin ligase. R1, R2, R3, M1, M2, M3, L1, L2, and L3 are as defined herein.

ASYMMETRIC TRIAZOLE BENZAMIDE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME

The present disclosure is directed to asymmetric triazole benzamide compounds of formula (I) and formula (II), pharmaceutical compositions thereof and methods for modulating or activating a Parkin ligase The present disclosure is also directed to methods of treating and/or reducing the incidence of diseases or conditions related to the activation of Parkin ligase. R1, R2, R3, M1, M2, M3, L1, L2, and L3 are as defined herein.

METHODS FOR TREATING PATIENTS WITH CANCER HAVING DEFECTS IN CYCLIN D REGULATION

The present disclosure relates to methods of treating cancer comprising administering Parkin ligase activator or a pharmaceutically acceptable salt thereof to a subject who has a mutant form of a protein in the Rb checkpoint pathway. The Parkin ligase activator includes triazole compounds, such as compounds of formula (I), and pharmaceutically acceptable salts thereof as disclosed herein. R1, R2, R3, M1, M2, M3, L1, L2, and L3 are as defined herein.

TRIAZOLE BENZAMIDE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME

The present disclosure is directed to triazole benzamide compounds of formula (I) and formula (II), pharmaceutical compositions thereof and methods for modulating or activating a Parkin ligase The present disclosure is also directed to methods of treating and/or reducing the incidence of diseases or conditions related to the activation of Parkin ligase. R1, R2, R3, M1, M2, M3, L1, L2, and L3 are as defined herein.

Reaction of 1-substituted 3,5-diamino-1,2,4-triazoles with β-keto esters: synthesis and new rearrangement of mesoionic 3-amino-2H-[1,2,4]triazolo-[4,3-a]pyrimidin-5-ones

Reaction of 3,5-diamino-1-R-1,2,4-triazoles (R=Ph, Bn) with β-keto esters results in the reversible formation of N-(5-amino-1-R-1,2,4-triazol-3-yl)-substituted enaminoesters (8). Subsequent transformations depended on the reaction conditions. Compounds 8 undergo intermolecular reactions of condensation and amidation in the absence of solvent. However, in the presence of acetic acid they form 3-amino-5-oxo-2-R-2,5-dihydro-[1,2,4]triazolo[4,3-a]pyrimidin-4-ium-8-id es (10) followed by rearrangement to 3-amino-1-R-[1,2,4]triazolo[4,3-a]pyrimidin-5-ones (11). The transformation of 10 into 11 represents a new type of rearrangement in the azolopyrimidine series. Heating of enaminoesters 8 in ethanol with sodium ethoxide present, proved to be a suitable method for the preparation of the mesoionic compounds 10.